Reports Q3 revenue $1.08M, consensus $1.64M. “With the completion of the transformative sale of our FibroGen (FGEN) China operations, we have significantly simplified our capital structure and extended our cash runway into 2028. Notably, we initiated the Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis anticipated in the second half of 2026,” said Thane Wettig, Chief Executive Officer, FibroGen. “We remain on track to submit the Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025 and continue to assess its development options. We are excited to continue building on the strong momentum we have gained throughout this year.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FGEN Upcoming Earnings Report: What to Expect?
- FibroGen Receives $6.4 Million Payment from AstraZeneca
- Hold Rating on FibroGen’s FG-3246 Amid Competitive Prostate Cancer Treatment Landscape and Upcoming Trial Data
- FibroGen’s Strategic and Financial Advancements: A Positive Outlook on FG-3246 and Roxadustat
- FibroGen initiates Phase 2 trial of FG-3246